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OBJECTIVES: Performing a basic evaluation of a resi-
dent’s urinary incontinence (UI) condition is needed to
determine the cause of the incontinence and guide appro-
priate treatment. The two objectives of this study were 1)
to determine the prevalence of residents with UI that
received one or more of the four parts of the Agency for
Health Care Policy and Research (AHCPR) basic evalu-
ation guidelines, and 2) to compare the effectiveness of
two types of oral antimuscarinic medications—toltero-
dine and oxybutynin. METHODS: Data were extracted
from medical and Minimum Data Set records in 30
nursing homes in 5 regions of Texas. RESULTS: For
Objective 1, medical charts of 255 residents were
reviewed. There were 64 residents that met the study cri-
teria for Objective 2. Regarding Objective 1, the major-
ity (n = 179, 70.2 percent) had no documentation of any
part of the basic evaluation that is recommended for
patients with urinary incontinence. Fifty-seven patients
(22.3 percent) had documentation of one part of the eval-
uation, while less than 8% (n = 19) had two or more parts
of the basic evaluation documented. Female residents
were more likely than male residents to have one or more
parts of the basic evaluation performed. Residents resid-
ing in nursing homes located in urban areas were more
likely to have one or more parts of the basic evaluation
performed compared to residents residing in rural setting
nursing homes. For Objective 2, results showed that 
residents receiving tolterodine had a greater decrease in
urinary incontinence severity levels than residents receiv-
ing oxybutynin. Female residents had a greater improve-
ment in UI levels than male residents. CONCLUSIONS:
The sparse documentation of basic urinary incontinence
evaluations indicates that health care providers and deci-
sion makers need to continue to focus on ways to improve
the evaluation and management of urinary incontinence
in elderly nursing home residents.
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OBJECTIVES: To identify the range of clinical manage-
ment strategies used to reduce CMV infection and disease
following renal transplantation in France. METHODS: A
questionnaire-based survey tool was developed over a
three-month period, with review provided by an expert
committee consisting of three clinicians and a leading
health economist. The ﬁnalised questionnaire was sent
out to the 35 centres for adults existing throughout
France. The questionnaire requested information on the
number of transplanted patients, the proportions of
patients in recognised CMV risk groups based on donor
and recipient CMV status, the types of risk reduction
strategies adopted, the treatment protocols for CMV
disease and ﬁnally the incidence of CMV disease by risk
group. Respondents were asked to use actual data records
wherever possible. RESULTS: Overall 31 centres com-
pleted the survey, a response rate of 89%. The centres
performed 1641 adult transplantations during the year
2000. The average number of patients per centre was 53,
ranging between 20 to 140 per year. Around 25% of
patients were considered at low-risk of CMV (D-R-),
50% were R+ and 30% were D+R-. However, the dis-
tribution of patients varied greatly across centres. The
most commonly adopted strategy in the D+R- group 
was prophylaxis using oral valaciclovir. In the remaining
patients most centres used close monitoring with pre-
emptive drug treatment using oral ganciclovir or valaci-
clovir. Altogether, there were around 250 cases of CMV,
approximately 30% being tissue invasive disease and
70% general symptoms only. CONCLUSION: The
survey conﬁrms the wide variation of patient types across
centres in France. The CMV incidence results also
conﬁrm the increased risk faced by the D+R- patient
group, which may be enhanced further through the wide-
spread use of antilymphocyte therapy. Although pro-
phylaxis treatment appears widely used in higher–risk
patients, around 20% of centres currently wait until 
the presentation of CMV symptoms before initiating
treatment.
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OBJECTIVES: Heavy menstrual bleeding is experienced
by a large number (approx. 13%) of women and precip-
itates considerable use of health care. We estimate the use
of resources for women with increased bleeding, using a
population health survey. METHODS: The database used
is the 1999 United States National Health Interview
Survey (NHIS). The study population is all women age
18 and above. The dependent variables are categorical,
indicating whether or not women used a series of health
care services. The independent variables comprise the
study variable (indicating increased menstrual ﬂow) 
and demographic and socioeconomic variables. Logistic
regressions were run for each type of service. RESULTS:
In the sample of 2805 women, 373 (13.3 per cent) 
women had increased menstrual ﬂow. The odds ratio,
indicating the net impact of increased ﬂow was estimated
for the following services (* indicates signiﬁcant at .05
level): general practitioners, 1.48*; emergency room,
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1.78*; home care, 2.02*; surgery, 1.56*; specialist visits,
1.23; prescription drugs, 1.27. CONCLUSION: Heavy
menstrual ﬂow occurs in 13% of women over age 18, and
is associated with increased use of emergency room visits
and surgery, but not OBGYN or other specialist visits 
or prescription drugs. The results may be interpreted to
mean that many women seek temporary solutions (ER
visits) and may avoid certain types of care, including
drugs.
PWM2
COST ANALYSIS OF IVF TREATMENT WITH
INJECTION DEVICE VS THE TRADITIONAL
SYRINGE AND NEEDLE
Johannes E1, Brown RE2
1Organon, Oss, Netherlands; 2MEDTAP, London, UK
The Puregon Pen is a patented medical precision device
to administer follitropin beta solution—recombinant
FSH—for infertility treatment. The Pen can be used for
multiple treatment cycles and requires less RecFSH per
cycle than the traditional syringe and needle. OBJEC-
TIVE: Evaluate the cost consequences of the Puregon 
Pen on the total direct medical costs of an IVF cycle.
METHOD: A Markov model in Excel is used to calcu-
late the total direct medical costs per patient per IVF cycle
using the Pen with follitropin beta solution in a cartridge
versus a traditional syringe and needle with follitropin
alpha powder and solvent for solution. Treatment transi-
tion probabilities and total volume of RecFSH use per IVF
cycle are obtained from published data. Costs are based
on average European prices. RESULTS: The published
data showed an average reduction in RecFSH use with
the Pen of 15.5% (345IU, p < 0.001) compared to the
traditional syringe and needle. Treatment duration was
shorter with the Pen (10.8 vs. 12 days, p = 0.001). No
differences in medical treatment and follow-up or in the
vital pregnancy rate per embryo transfer were identiﬁed.
Using an average European price of €0.55/IU for both
RecFSH products and €100 for the device, the average
total direct medical costs when using the Pen may be
reduced by €90 in the ﬁrst IVF cycle. Every additional IVF
cycle using the Pen may generate an average cost offset
of €190. CONCLUSION: Costs associated with pur-
chasing the Puregon Pen can be offset through shorter
infertility treatment time and less RecFSH use per cycle.
WOMEN’S AND MEN’S HEALTH—Clinical
Outcomes
PWM3
SECOND-GENERATION VERSUS FIRST-
GENERATION ENDOMETRIAL ABLATION
TECHNIQUES IN THE TREATMENT OF
DYSFUNCTIONAL UTERINE BLEEDING (DUB):A
REVIEW OF THE LITERATURE
Lessard C, Framarin A
Agency for Health Services and Technology Assessment
(AETMIS), Montreal, QC, Canada
OBJECTIVES: Traditional hysteroscopic endometrial
ablation techniques are safe and effective though under-
utilized, mainly because of the procedures required spe-
cialized training and had perceived risks. Several new
technologies have been developed; most of which are
blind techniques. A review of the literature was under-
taken to compare the efﬁcacy, safety and acceptability of
second- versus ﬁrst-generation endometrial ablation tech-
niques in DUB. METHODS: Medline, Current Contents,
Cochrane Library, NHS Centre for Reviews and Dissem-
ination and FDA Center for Devices and Radiological
Health were searched from 1981 to March 2002. Bibli-
ographies of relevant articles were screened. Industries
and authors were contacted for information on published
or unpublished data. Experts in the ﬁeld were consulted.
RCTs comparing endometrial ablation techniques in DUB
were eligible for inclusion. Trials of techniques aban-
doned at the time of the review or not published in
English or French were excluded. Outcomes were men-
strual blood loss, satisfaction, quality of life, operative
details, complications, and requirement for further
surgery. RESULTS: Five RCTs were included. They eval-
uated ﬁve new technologies and assessed outcomes one
year after surgery. One trial had long-term follow-up.
Compared to ﬁrst-generation techniques, new technolo-
gies had consistently shorter durations of surgery (11–
27min vs 15–40min), more surgeries performed under
local anesthesia (45–73% vs 8–24%), and fewer intra-
operative complications (0–1,1% vs 2,4–5,8%). At 12
months, clinical outcomes results were similar between
the 2 generations. Results remained similar, with little dif-
ference at three years compared with results at one year.
CONCLUSION: There was no clear difference in clinical
outcomes between second- and ﬁrst-generation tech-
niques. Advantages include ease of use, short operative
time, choice of anesthesia and reduced risk of intraoper-
ative complications. Risk of inadvertent perforation and
subsequent injury to bowel exists. Long-term safety and
efﬁcacy, cost-effectiveness and safety in use by the general
gynecologist remain to be studied.
WOMEN’S AND MEN’S HEALTH—Quality of
Life/Utility
PWM4
INFLUENCE OF ERECTILE DYSFUNCTION ON
HEALTH RELATED QUALITY OF LIFE OF MALE
KIDNEY TRANSPLANT PATIENTS ACCORDING
TO AGE
Rebollo P1, Ortega F1, Fernandez-Vega F2,Valdés C1,
Ortega T1
1Hospital Central de Asturias and Institute “Reina Soﬁa” for
Nephrological Research, Asturias, Spain; 2Hospital Central de
Asturias, Asturias, Spain
OBJECTIVE: There is some evidence that aging deterio-
rates the Health Related Quality of Life (HRQOL) in
physical area, although mental area remains stable, even
suffering chronic diseases, because of adaptation mecha-
